GlassScriptPhysician profile
Farshid Ighani
NPI 1295939866
$3,937.29
in general payments reported to CMS, 2019-2025
22 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $77.90 · 2021: $435 · 2022: $329 · 2023: $2,070 · 2024: $524 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,397 · Food and Beverage: $1,294 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,396.54 |
| Food and Beverage | $1,293.80 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $1,539.90 | 2022-2023 | Veracity Surgical, Iolmaster 700, Cirrus Hd-Oct |
| Alcon Vision LLC | $990.98 | 2019-2025 | Clareon, Centurion, Argos |
| Aerie Pharmaceuticals, INC. | $230.75 | 2019-2021 | |
| Allergan, INC. | $201.54 | 2019-2022 | |
| Abbvie INC. | $196.20 | 2022-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $185.18 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Seagen INC. | $99.99 | 2023 | |
| Novartis Pharmaceuticals Corporation | $86.44 | 2019-2023 | |
| Biotissue Holdings INC. | $55.96 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $46.03 | 2022-2024 | |
| Sight Sciences, INC. | $40.81 | 2022-2024 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $32.77 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $31.94 | 2019-2020 | |
| Glaukos Corporation | $30.64 | 2024 | Idose |
| Oyster Point Pharma, INC. | $26.13 | 2023 | Tyrvaya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.39 | 2025 | Blenrep |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.97 | 2019 | |
| Kala Pharmaceuticals, INC. | $23.03 | 2021 | |
| Beaver-Visitec International, INC. | $20.79 | 2020 | |
| Dompe US, INC. | $19.72 | 2025 | Oxervate |
| Amgen INC. | $15.24 | 2025 | Tepezza |
| Rxsight INC | $14.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farshid Ighani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.